BPMX

BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trial for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in San Jose, California....

+See More

Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 20 December 2025